Chemokine receptor antagonists

Medicinal Research Reviews

Volumn 20, Issue 2, 2000, Pages 155-168

  Horuk, Richard ^a   Ng, Howard P ^a,b  

^a BAYER AG   (Germany)

^b Coulter Pharmaceutical ^*  (United States)

Author keywords

Antagonists; Autoimmunity; Chemokines; Proinflammatory disease

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EOTAXIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 2; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; AUTOIMMUNITY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS;

ARTERIOSCLEROSIS; AUTOIMMUNE DISEASES; CHEMOKINES; HUMANS; ORGAN TRANSPLANTATION; RECEPTORS, CHEMOKINE; SKIN DISEASES;

EID: 0034009295     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(200003)20:2<155::AID-MED3>3.0.CO;2-G     Document Type: Article

References (56)

1. Baggiolini M, Clark-Lewis, I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992;307:97-101.
2. Horuk R. In: Pharmacology and toxicology: basic and clinical aspects. Hollinger MA. editor. Boca Raton: CRC; 1996. p 377.
3. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-638.
4. D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors - Confluence of two fields generates optimism in AIDS research. Nature Med 1996;2:1293-1300.
5. Schall T. The chemokines. In: Thompson A, editor. The cytokine handbook. San Diego; Academic; 1994. p 419-460.
6. Baggiolini, M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
7. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine, Eotaxin, activates guinea-pig eosinophils in vitro, and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993;197:1167-1172.
8. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ. Model systems for the study of seven transmembrane-segment receptors. Ann Rev Biochem 1991;60:653-688.
9. Horn F, Weare J, Beukers MW, Horsch S, Bairoch A, Chen W, Edvardsen O, Campagne F, Vriend G. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res 1998;26:275-279.
10. Ebers GC. Multiple sclerosis and other demyelinating disease. In: Asbury AK, McKhann GM, McDonald WI, editors. Diseases of the nervous system. Philadelphia: Ardmore; 1986. p 1268-1281.
11. Strieter RM, Kunkel SL, Showell HJ, Rennick DJ, Phan SH, Ward RA, Marks RM. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989;243:1467-1469.
12. Huber AR, Kunkel SL, Todd RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991;254:99-102.
13. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:167-176.
14. Glabinski AR, Tani M, Tuohy VK, Ransohoff RM. Murine experimental autoimmune encephalomyelitis: A model of immune-mediated inflammation and multiple sclerosis. Methods Enzymol 1997;288:182-190.
15. Miyagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K. Identification of cell types producing RANTES MIP-1 alpha and MIP-1 beta in rate experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 1997;77:17-26.
16. Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM. Synchronous synthesis of α- and β-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997;150:617-630.
17. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-5010.
18. Karpus WJ, Kennedy KJ. MIP-1 alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Bio 1997;62:681-687.
19. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. J Bio Chem 1993;268:5834-5839.
20. Snowden N, Hajeer A, Thomson W, Ollier B. RANTES role in rheumatoid arthritis. Lancet 1994;343:547-548.
21. Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, Horuk R, Daniel Perez H. Polyclonal antibody directed against human RANTES ameliorates disease in the lewis rat adjuvant-induced arthritis model. J Clin Invest 1998;101:2910-2919.
22. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AEI, Power CA, Wells TNC. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997;57:117-120.
23. Pattison J, Nelson PJ, Huie P, Von LI, Farshid G, Sibley RK, Krensky AM. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994;343:209-211.
24. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997;99:2682-2690.
25. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Hearth Lung Transplant 1996;15:1194-1199.
26. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplant 1997;63:414-420.
27. Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999;79:9-11.
28. Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K, Nishioka K, Katayama I. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D/n3 (tacalcitol). Br J Dermatol 1998;138:63-70.
29. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 1997;122:749-757.
30. Yu X, Dluz S, Graves DT, Zhang L, Antoniades NH, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-6957.
31. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-5256.
32. Takeya M, Yoshimura T, Leonard EJ, Kato T, Okabe H, Takahashi K. Production of monocyte chemoattractant protein-1 by malignant fibrous histiocytoma: relation to the origin of histiocyte-like cells. Exp Mol Pathol 1991;54:61-71.
33. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-1127.
34. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
35. Hesselgesser J, Ng HP, Liang M, Zheng W, May K, Bauman JG, Monahan S, Islam I, Wei GP, Ghannam A, Taub DD, Rosser M, Snider RM, Morrissey MM, Perez HD, Horuk R. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Bio Chem 1998; 273:15687-15692.
36. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmaco (Berlin) 1994;114:559-565.
37. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57 Suppl 11:4-11.
38. Kato K, Yamamoto M, Honda S, Fujisawa T. Use of heterocyclic derivatives as MIP-1α/R ANTES antagonists useful for treating e.g. inflammatory and allergic diseases, arteriosclerosis, asthma and multiple sclerosis. World (PCT) Patent WO-9724325, 1997.
39. Naya A, Owada Y, Saeki T, Ohkawi K, Iwasawa K. New fused compounds are chemokine antagonists-useful for the treatment and prevention of acute and chronic inflammatory disorders AIDS, cancer, ischemic reflow disorders and arteriosclerosis. World (PCT) Patent W0-9804554, 1998.
40. Mills SG, Springer MS, MacCoss M. Spiro-substituted azacycles as modulators of chemokine receptor activity. World (PCT) Patent W0-9825605, 1998.
41. Mills SG, Springer MS, MacCoss M. Substituted aryl piperazinesas modulators of chemokine receptor activity. World (PTC) Patent WO-9825617, 1998.
42. Hagmann WK, Springer MS. Substituted aminoquinolines as modulators of chemokine receptor activity. World (PTC) Patent WO-9827815, 1998.
43. Brown MF, Kath JC, Poss CS. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCR1 receptor. World (PCT) Patent W0-9838167, 1998.
44. Howard OM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, Buckheit RW Jr, Clanton DJ, Turpin JA, Rice WG. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem 1998;41:2184-2193.
45. Proudfoot AEI, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TNC. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Bio Chem 1996;271:2599-2603.
46. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AEI. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
47. LaRosa GJ, Carson KG, Glase SA, Reinhart AL, Unangst PC, Kellner D. In: 26th Nat Med Chem Symp, Richmond, VA, 1998.
48. Lapierre JM, Morgans D, Wilhelm R, Mirzadagean TR. In: 26th Nat Med Chem Symp, Richmond, VA, 1998.
49. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
50. Elliot JD, Leber JD, Thompson SK, Halbert SM. Novel carboxylic acid indole compounds for treatment of disease states mediated by interleukin-8. World (PTC) Patent WO-9618393, 1996.
51. Widdowson, KL, Verber DF, Jurewicz AJ, Rutledge MC. IL-8 receptor antagonists. World (PTC) Patent WO-9625157, 1996.
52. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Bio Chem 1998;273:10095-10098.
53. Schols D, Struyf S, Damme JV, Est JA, Henson G, Clercq ED. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
54. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
55. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734-739.
56. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992;89:5286-5290.